One Shot, Double Protection: CRI-Kasauli Develops Breakthrough Tetanus-Diphtheria Vaccine
India’s public health programme has received a major boost with scientists at the Central Research Institute (CRI), Kasauli developing a single-dose vaccine that protects against both tetanus and diphtheria.
The vaccine, which has successfully cleared clinical trials, is expected to be rolled out in government hospitals soon after its formal launch by Union Health Minister JP Nadda.
From Two Injections to One
Until now, patients—especially children—had to endure separate injections for tetanus and diphtheria. In 2019, CRI researchers began working on a combined formulation, continuing their efforts even through the Covid-19 pandemic. Their breakthrough now promises to simplify immunisation schedules, reduce healthcare burdens, and improve compliance.
Clinical Trials Confirm Success
Trials showed strong antibody responses against both diseases, meeting all safety standards. Health experts say the vaccine will play a crucial role in preventing tetanus (often caused by cuts and wounds) and diphtheria, a contagious illness that primarily affects children but can strike at any age.
A Legacy of Innovation
Founded in 1905, CRI-Kasauli has long been a cornerstone of India’s vaccine research. From producing the country’s first DPT vaccine to treating soldiers during World War II, the institute has consistently advanced public health. With this new combined vaccine, CRI has once again proven its role as a pillar of India’s immunisation efforts.
